ClinicalTrials.gov
ClinicalTrials.gov Menu

Riociguat for Sarcoidosis Associated Pulmonary Hypertension (RioSAPH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02625558
Recruitment Status : Recruiting
First Posted : December 9, 2015
Last Update Posted : December 9, 2015
Sponsor:
Information provided by (Responsible Party):
Robert P Baughman, University of Cincinnati

Brief Summary:
Double blind placebo controlled trial of riociguat for sarcoidosis associated pulmonary hypertension

Condition or disease Intervention/treatment Phase
Sarcoidosis Drug: Riociguat Drug: Placebo Phase 4

Detailed Description:

Study design Patients will be recruited into double blind randomized trial of riociguat with 1:1 active drug to placebo. The table below summarizes the study design. Patients will have previously undergone right heart catheterization (RHC) within six months of initial dose dispensation and with no significant change in treatment for pulmonary hypertension. Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day.

The patient will be treated for 48 weeks or until clinical worsening of disease. An adjudication committee will review all cases of clinical worsening. This committee will be blinded to treatment. The determination by the adjudication committee will be used as the final determinant for the primary end point.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension
Study Start Date : April 2015
Estimated Primary Completion Date : April 2018
Estimated Study Completion Date : October 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Riociguat

Arm Intervention/treatment
Active Comparator: Riociguat
Active drug
Drug: Riociguat
Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day
Other Name: Rio

Placebo Comparator: Placebo
placebo
Drug: Placebo
Placebo given three times a day




Primary Outcome Measures :
  1. Time until clinical worsening [ Time Frame: 48 weeks ]
    Patient shows deterioration using fixed criteria


Secondary Outcome Measures :
  1. Safety: adverse events [ Time Frame: 48 weeks ]
    adverse events

  2. Pulmonary function [ Time Frame: 48 weeks ]
    Changes in FVC

  3. Quality of life [ Time Frame: 48 weeks ]
    Changes in QOL using general and sarcoidosis specific instruments

  4. Six minute walk [ Time Frame: 48 weeks ]
    Change in six minute walk distance



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with diagnosis of sarcoidosis
  • Age ≥ 18 years.
  • Life expectancy of at least 2 years.
  • Subjects must be able to understand and be willing to sign the written informed consent form. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.
  • Females of reproductive potential (FRP) must have a negative, pre-treatment pregnancy test.
  • FRP must obtain monthly pregnancy tests during treatment and one month after treatment discontinuation. Post-menopausal women (defined as no menses for at least 1 year or post-surgical from bilateral oophorectomy) and surgically sterilized women are not required to undergo a pregnancy test.
  • Females of reproductive potential and all non-vasectomized male participants must agree to use reliable contraception when sexually active.
  • Subjects (males and females) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 30 days after the last dose of study drug.
  • Willing and able to comply with the protocol, including follow-up visits and examinations

Exclusion Criteria:

  • Patients with an FVC of less than 30% of predicted during screening visit.
  • Patients with severe airway obstruction
  • Patients unable to perform the 6 minute walk test
  • Pregnant women (i.e. positive serum ß-human chorionic gonadotropin test or other signs of pregnancy),
  • Breast feeding women
  • FRP not using reliable contraception as recommended in the Prescriber Guide for the riociguat pregnancy monitoring program
  • Subjects with a medical disorder, condition, or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator
  • Known significant left heart disease:
  • Pulmonary venous hypertension indicated by baseline pulmonary capillary wedge pressure > 15 mmHg
  • Active state or history of hemoptysis or pulmonary hemorrhage
  • Subjects requiring nitrates for any reason
  • Subject using nitrates within one month of entering study
  • Pulmonary veno-occlusive disease
  • Subjects with underlying medical disorders with an anticipated life expectancy below 2 years (e.g. active cancer disease with localized and/or metastasized tumor).
  • Subjects with hypersensitivity to the investigational drug or any of the excipients.
  • Women who are pregnant or breast-feeding.
  • Severe proven or suspected coronary artery disease
  • Clinical relevant hepatic dysfunction indicated by: bilirubin >2 times upper limit normal at Visit 0 and/or: alanine aminotransferase (ALT) or AST aspartate aminotransferase (AST) >3 times upper limit normal at Visit 0 and/or: signs of severe hepatic insufficiency (e.g. impaired albumin synthesis with an albumin <32 g/L, hepatic encephalopathy > grade 1a) at Visit 0

West Haven Criteria of Altered Mental Status in Hepatic Encephalopathy

  • Severe renal insufficiency indicated by a glomerular filtration rate <30 mL/min at Visit 0, e.g. calculated based on the Cockcroft formula or the Modification of Diet in Renal Disease Study Group (MDRD) formula
  • Inability to comply with the protocol and/or not willing or not available for follow-up assessments.
  • Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation.

Excluded therapies and medications, previous and concomitant

  • Specific (e.g. sildenafil or tadalafil) or unspecific phosphodiesterase inhibitors (e.g. dipyridamole, theophylline).
  • NO donors (e.g. nitrates). Single applications of vasoactive drugs in connection with diagnostic vasoreactive testing are allowed.
  • Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form).
  • Major surgery within 30 days prior to start of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02625558


Contacts
Contact: Robert P Baughman, MD 513-584-5225 bob.baughman@uc.edu

Locations
United States, Ohio
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45267
Contact: Felicia Thompson    513-584-6252    THOMPSFA@ucmail.uc.edu   
Principal Investigator: Robert P Baughman, MD         
Sponsors and Collaborators
University of Cincinnati
Investigators
Principal Investigator: Robert P Baughman, MD University of Cincinnati
Principal Investigator: Steve Nathan, MD Inova Fairfax Hospital

Responsible Party: Robert P Baughman, Professor, University of Cincinnati
ClinicalTrials.gov Identifier: NCT02625558     History of Changes
Other Study ID Numbers: 2014-7130
First Posted: December 9, 2015    Key Record Dates
Last Update Posted: December 9, 2015
Last Verified: December 2015

Keywords provided by Robert P Baughman, University of Cincinnati:
riociguat
saph
sarcoidosis
sarcoidosis associated pulmonary hypertension

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Sarcoidosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Lymphoproliferative Disorders
Lymphatic Diseases